Podcasts about Chronic kidney disease

View the Show Notes For This Episode Dr. Robin Rose discusses Kidney Care with Peptides with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights In this episode of the Rational Wellness Podcast, Dr. Ben Weitz hosts Dr. Robin Rose to discuss crucial insights into kidney health. They explore the kidney's functions, including filtering blood, regulating electrolytes, and converting vitamin D. The conversation delves into chronic kidney disease, highlighting that symptoms can arise even in stage two when GFR drops below 60. Dr. Rose emphasizes the importance of early detection and intervention, discussing concepts such as uremic dysbiosis, endothelial damage, leaky gut, and the impact of toxins. They also touch on natural and supplemental approaches to support kidney health, like using bio-regulator peptides, nutritional therapy, and plant-based diets. Additionally, Dr. Rose shares her personal experience with kidney cancer and the insights she gained during her journey to recovery.   00:26 Understanding Kidney Functions and Chronic Kidney Disease 02:10 In-Depth Discussion with Dr. Robin Rose 02:34 The Complexities of Kidney Health 04:28 Kidney and Gut Health Connection 04:54 Challenges in Measuring Kidney Function 08:48 Managing Kidney Health Through Diet and Lifestyle 28:43 Nutritional Supplements for Kidney Health 33:23 Butyrate and Gut Health 33:56 Cardiovascular Markers and Genomics 34:59 Kidney Health Botanicals 37:31 Peptides and Their Benefits 43:06 Bio-Regulator Peptides 51:31 Personal Kidney Health Journey 52:48 Hydration and Herbal Teas 54:40 Final Thoughts and Resources     ________________________________________________________________________________________________________ Dr. Robin Rose is a Medical Doctor and an expert at supporting kidney health using a wholistic approach and peptides.  She has recently published a book, Renology Peptides: Kidney Success with Bioregulator Peptides. Renology Peptides is a comprehensive clinical volume that presents an evidence-guided scholarly tool to deepen understanding of regenerative kidney medicine and bioregulator peptides. Her website is Renology is Kidney Success.    Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

A research team led by Kyoto University said Wednesday it has successfully prevented kidney functions from declining in mice using human induced pluripotent stem cells, or human iPS cells, an achievement that may lead to the development of an effective therapy for chronic kidney disease.

https://www.nejm.org/doi/full/10.1056/NEJMoa2204233

This podcast will discuss an approach to pediatric chronic kidney disease. The podcast was created by Alexis Filyk, a second-year medical student at the University of Alberta, and Dr. Michelle Ruhl, a pediatric nephrologist at the Stollery Children's Hospital in Edmonton, Alberta.

Big Pharma pays billions for direct-to-consumer TV drug ads—is it time to ban them? Focused ultrasound obliterates liver tumors with minimal side effects; Nurse tricks woman into believing she's dying of cancer to cash in on her $1.5 million life insurance policy; Arizona bans insurance denial by AI automated systems; Study overturns view that very low-carb diets are bad for kidney disease patients; Strategies for reviving a lagging thyroid.

Why does a potentially deadly condition that affects 1 in 7 adults fly under the radar, undetected and undiscussed? Join us on this episode of Quality Matters as we explore Chronic Kidney Disease (CKD), a silent killer that's finally coming into the limelight of quality improvement.Our conversation begins with Dr. Ben Oldfield, a primary care physician, who sheds light on the startling prevalence and hidden complexities of CKD. Why is it so hard to detect, even with simple blood and urine tests? And why does this condition, despite its extensive impact, often get lost in the shuffle of busy health care visits?We'll unpack the challenges of diagnosing and managing CKD, exploring the emotional weight the diagnosis carries for patients and the hurdles clinicians face in communicating about it. Discover why CKD is a “loaded term” and how we can shift the narrative from fear to empowerment.But that's not all. We'll also tackle the big picture: How CKD fits into the broader landscape of cardiovascular, kidney, and metabolic (CKM) disorders. Could a holistic approach to these interconnected conditions revolutionize patient care?The conversation ends with Ben's thoughtful observations on how classic literature, particularly epic poetry, helps doctors make sense of health care's emotional complexities, connect with patients and find empowerment in the face of life and death.Join us as we explore how we can move CKD from the sidelines to the front lines of quality improvement, and how collaborative, longitudinal care can make a real difference.Key Quote:“Thinking about chronic kidney disease is a longitudinal process. It's only half the story to make the diagnosis in a snapshot in time. What's the follow up like? How are we doing with the patient over time? Because oftentimes quality measures can look at things in a snapshot in time. Chronic kidney disease really begs us to think more longitudinally.”“Benjamin Oldfield, MDTime Stamps:(02:54) The Silent Nature of CKD(07:05) Quality Measurement and CKD(11:08) The Link Between CKD and Cardiovascular Kidney Metabolic syndrome(13:06) CKD and CKM as Quality Priorities (15:45) Narrative Medicine and Personal InsightsLinks:NCQA Kidney Health ToolkitConnect with Benjamin Oldfield

Gugs Mhlungu and Resident GP & CEO of Proactive Health Solutions, Dr Fundile Nyati shine the spotlight on World Kidney Day, under the theme “Are Your Kidneys OK? Detect early, protect kidney health.” And give some advice on kidney disease risk factors and emphasize the importance of early detection. See omnystudio.com/listener for privacy information.

The Clare branch of the Irish Kidney Assocation says it's "lobbying very hard" for a dialysis unit in Clare this World Kidney Day. In conjunction with the annual awareness day which has rolled around again, the Irish Kidney Association, or IKA, has launched its '1 in 10 People' campaign to shine a light on kidney health awareness. The campaign, according to the IKA, is intended to make people more aware of kidney-related health conditions. It's estimated that one in 10 people in Ireland and one in seven over the age of 50 are living with Chronic Kidney Disease or CKD. Of these, a startling 98% don't know they have the condition which is on track to be the fifth leading cause of death here by 2040. Clare people in need of renal care currently have to go either to University Hospital Limerick or its satellite centre on the Dock Road in Limerick. While the HSE had at one point said Ennis Hospital would have a dialysis unit by the end of this year, this has now been pushed back to November 2026. Chairperson of the Clare branch of the IKA Dermot Hayes people here are travelling an exceptional distance to access the care they need. At this week's meeting of Clare County Council, Clarecastle Sinn Féín Councillor Tommy Guilfoyle tabled a motion seeking clarity on the delivery of the Ennis dialysis unit. Specifically, he's requested a precise timeline on the commencement of services, confirmation of its location, details of the contractor and confirmation of the project's current status. He says many in this county are confused and need answers as a matter of urgency.

A new study by researchers at the University of Limerick has revealed an extraordinarily high burden of kidney disease in older individuals in Ireland that suffer from common chronic conditions. We hear from Professor Austin Stack, Senior Author on the study and Consultant Nephrologist at UL.

As the world marks World Kidney Day today, South Africa is seeing a rise in chronic kidney disease cases. Dr. Karisha Quarrie, Chief Medical Officer at Life Healthcare says a holistic approach is needed to effectively manage this life-threatening condition. Dr. Quarrie spoke to Elvis Presslin

Professor Austin Stack and Alceina O'Brien join Gillian on World Kidney Day to raise awareness for Chronic Kidney Disease, which 1 in 10 Irish people suffer from Hosted on Acast. See acast.com/privacy for more information.

Dr. Kirk Welker is Dr. Hiatt's guest this month. They discuss the research and collaboration involved in creating the State of Practice: ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease, published in the February issue of AJNR. Be sure to visit our website to watch the video version of this podcast. (13:04)

Send us a textIn this episode, we have Dr. Lisa Dubrofsky (Nephrology, University of Toronto) speaking about the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.Host: Dr. Catherine Leurer (Geriatrics Fellow)Sound editing by:  Krzystof KowalikSupport the show

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826241296668

BUFFALO, NY- January 28, 2025 – A new #research paper was #published in Volume 16, Issue 22 of Aging (Aging-US) on December 20, 2024, titled, “Impaired renal transporter gene expression and uremic toxin excretion as aging hallmarks in cats with naturally occurring chronic kidney disease.” This study, led by researchers Qinghong Li, James A. Holzwarth, Bethany Smith, Sonia Karaz, Mathieu Membrez, Vincenzo Sorrentino, Stacie Summers, Julie Spears, and Eugenia Migliavacca from Nestlé Purina Research and Oregon State University, explores how aging affects kidney function in cats with chronic kidney disease (CKD). The researchers found that older cats have lower levels of important kidney transporter genes, which usually help remove harmful waste products from the blood. These findings could help veterinarians better understand CKD in aging cats and offer insights that may be relevant to human kidney health. "Chronic kidney disease (CKD) is a naturally occurring kidney disease common in both geriatric cats and older people. Despite differing etiology, both species share many pathophysiological similarities, including chronic tubulointerstitial inflammation and fibrosis." Older cats with CKD struggle to filter toxins from their bloodstream effectively. In this study, the researchers analyzed kidney samples from two cat cohorts aged 6 to 21 years. The cohort number one included 41 colony cats: 28 control and 13 CKD cats. The cohort number two had 30 privately owned cats with 10 control and 20 CKD cats. They discovered that certain transporter genes, such as OAT1, OAT4, OATP4C1 and ABCC2, were significantly decreased in cats with CKD compared to healthy cats. The research team also found increased levels of harmful toxins in the blood of cats with CKD. Even healthy older cats had higher toxin levels compared to younger cats, showing that aging itself might contribute to declining kidney function. Monitoring kidney transporters levels and toxin buildup may help detect the disease early and improve treatment options. The researchers highlight the importance of regular veterinary check-ups to catch kidney problems early and keep cats healthier for longer. Because cats and humans share similar kidney health challenges, studying feline CKD can provide valuable insights into human kidney disease and aging. Continued research is essential to develop treatments that may improve kidney function in aging cats and potentially benefit humans as well. DOI - https://doi.org/10.18632/aging.206176 Corresponding author - Qinghong Li - qinghong.li@rd.nestle.com Video short - https://www.youtube.com/watch?v=WuEP9PXtx2A Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206176 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, trimethylamine N-oxide, indoxyl sulfate, OAT1, OATP4C1, ABCC2 About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Nephrologist Manjula Tamura discusses the downsides of kidney dialysis, especially for old or frail patients. Her field has set its sights on offering alternatives, including supportive medical management without dialysis, dialysis in increments, wearable artificial kidneys, and transplanted kidneys from genetically modified pigs – in addition to advances in preventive care that can help humans avoid kidney failure in the first place. Dialysis can extend life, she says, but it is a lifestyle change. The goal is to ensure that every patient's choice aligns with their values and life goals, Tamura tells host Russ Altman in this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Manjula Kurella TamuraConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest, Manjula Tamura, a professor of medicine and nephrology at Stanford University Medical School.(00:02:58) The Kidney's Vital RoleThe kidney's role and why its failure is life-threatening.(00:04:51) Causes of Kidney FailureThe leading causes of kidney failure in developed countries.(00:07:58) Kidney TransplantationThe feasibility, barriers, and supply challenges of kidney transplantation.(00:09:50) The Dialysis ProcessHow hemodialysis and peritoneal dialysis work and patient experiences.(00:14:07) The Evolution of Dialysis TreatmentThe history of dialysis and how Medicare's expansion influenced its use.(00:18:48) Study Design: Emulating Clinical TrialsUsing VA electronic health records to simulate trials on dialysis.(00:25:31) Findings: Survival vs. Time at HomeThe trade-offs between extended survival and reduced time at home.(00:27:02) Quality of Life and DialysisMeasuring quality of life impacts through electronic health records.(00:30:32) The Future of Kidney TreatmentsInnovations like xenotransplantation and wearable artificial kidneys.(00:33:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Chronic kidney disease develops among 30% to 40% of people with type 1 or type 2 diabetes during their lifetime. Author Ian H. de Boer, MD, MS, of the University of Washington Division of Nephrology, discusses the evaluation and treatment of chronic kidney disease in patients with type 1 and type 2 diabetes with JAMA Senior Editor Karen Lasser, MD, MPH. Related Content: Diabetes and Chronic Kidney Disease

Send us a textHappy Holidays Rounds Table Listeners! For our penultimate episode of 2024, we are back with a special treat! This week, Drs. Mike and John Fralick chat about the top five RCTs published over the past year:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (0:00 – 3:40).Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (3:40 – 9:00).Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (9:00 – 13:55).Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (13:55 – 20:00).Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (the Balance Trial) (20:00 – 23:30).And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (23:30 – 24:51).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePodsSupport the show

In this episode, we explore micronutrient considerations for persons living with chronic kidney disease, including risks, medications, laboratory monitoring and tips for completing effective nutrition screening and assessments in this patient population. Melissa Prest DCN, RDN, LDN, is the founder and owner of Kidney Nutrition Specialists based in Seattle, WA. Her past experience includes working as the Foundation Dietitian for the National Kidney Foundation of Illinois and in a dialysis center providing medical nutrition therapy for individuals treated with renal replacement therapy. This episode was recorded on 11/13/24 and is hosted by Christina M. Rollins, MBA, MS, RDN, LDN, FAND, CNSC.  

Happy Holidays Rounds Table Listeners! For our penultimate episode of 2024, we are back with a special treat! This week, Drs. Mike and John Fralick chat about the top five RCTs published over the past year:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (0:00 – 3:40).Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (3:40 – 9:00).Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (9:00 – 13:55).Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (13:55 – 20:00).Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (the Balance Trial) (20:00 – 23:30).And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (23:30 – 24:51).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Dr. Shika Pappoe, CMO and COO of Carna Health is working to identify and treat chronic kidney disease earlier through screening tests. This is a breakthrough for a disease that often shows no symptoms until the damage is irreversible. Using technology and AI-powered risk prediction models to improve early detection and intervention for CKD can help slow or even halt the progression of the disease. In recent pilot programs in Bermuda and Cameroon, Carna Health found high rates of CKD and is working to connect those patients with the necessary care.   Shika explains, "Chronic kidney disease is a condition that has been growing over the years. We know that diabetes and hypertension are leading causes, and currently, CKD is the 10th leading cause of death globally. And by 2040, it's estimated that it will be the fifth cause of death. Carna is working on finding ways to identify kidney disease early so that we can slow progression and optimize the outcomes of patients around the world." "We are seeing globally increasing rates of, again, diabetes and hypertension, the number one and two causes globally. Interestingly, communicable diseases have often been the priority in low- and middle-income countries. Still, we're seeing the rise of noncommunicable diseases such as CKD. I should say one of the other causes of this increasing epidemic is the environmental stressors, particularly heat. So. we see a lot of individuals who are working or living in very hot climates who are developing recurrent episodes of acute kidney injury, which ultimately leads to CKD. So, we have numerous causes for the increasing epidemic of CKD around the globe." #CarnaHealth #ChronicKidneyDisease #CKD #EarlyDetectionCKD Carna.Health Download the transcript here

Dr. Shika Pappoe, CMO and COO of Carna Health is working to identify and treat chronic kidney disease earlier through screening tests. This is a breakthrough for a disease that often shows no symptoms until the damage is irreversible. Using technology and AI-powered risk prediction models to improve early detection and intervention for CKD can help slow or even halt the progression of the disease. In recent pilot programs in Bermuda and Cameroon, Carna Health found high rates of CKD and is working to connect those patients with the necessary care.   Shika explains, "Chronic kidney disease is a condition that has been growing over the years. We know that diabetes and hypertension are leading causes, and currently, CKD is the 10th leading cause of death globally. And by 2040, it's estimated that it will be the fifth cause of death. Carna is working on finding ways to identify kidney disease early so that we can slow progression and optimize the outcomes of patients around the world." "We are seeing globally increasing rates of, again, diabetes and hypertension, the number one and two causes globally. Interestingly, communicable diseases have often been the priority in low- and middle-income countries. Still, we're seeing the rise of noncommunicable diseases such as CKD. I should say one of the other causes of this increasing epidemic is the environmental stressors, particularly heat. So. we see a lot of individuals who are working or living in very hot climates who are developing recurrent episodes of acute kidney injury, which ultimately leads to CKD. So, we have numerous causes for the increasing epidemic of CKD around the globe." #CarnaHealth #ChronicKidneyDisease #CKD #EarlyDetectionCKD Carna.Health Listen to the podcast here

Therapeutic strategies targeting the gut microbiome offer veterinarians promising interventions for managing chronic kidney disease (CKD) in cats. Tune in to this informative VetFolio Voice podcast episode to earn CE while learning about the important role of the gut-kidney axis in managing feline CKD. We address gut dysbiosis and its link to the accumulation of gut-derived uremic toxins in feline CKD patients, as well as options for caregivers that are unable to feed a renal therapeutic diet. Earn CE while learning about the importance of conducting a good history and asking open-ended questions in getting to the root cause of a behavioral issue. Want to earn CE from this episode? Be sure to log into VetFolio and take the quiz to qualify for your CE credit! https://www.vetfolio.com/courses/update-on-management-of-feline-chronic-kidney-disease-podcast-quiz

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Mark Sarnak from Tufts University in Boston. They discuss all aspects of cardiovascular risk in chronic kidney disease patients including how to mitigate the risk and future therapeutic areas. If you enjoy the show, please leave us a podcast review at https://itunes.apple.com/gb/podcast/heart-podcast/id445358212?mt=2 or wherever you get your podcasts - it's really helpful. This podcast was funded by the Boehringer Ingelheim and Lilly Alliance. The sponsor had no influence over the podcast content, including the selection of speakers or the approval of this episode. After you've listened to the episode, test your understanding of the topic by taking the free self-assessment module hosted on BMJ Learning at https://new-learning.bmj.com/course/30000268.

Host: Darryl S. Chutka, M.D.   Guest: Aleksandra Kukla, M.D. In 2023, an estimated 14% of all adults in the U.S. or just over 35 million individuals had chronic kidney disease and it's even more common in the elderly population affecting over 1/3 of those over the age of 65. It represents the 8th leading cause of death in the U.S. It's now known that chronic kidney disease is associated with systemic inflammation, which is responsible for a variety of complications including atherosclerosis and subsequent cardiovascular disease. Does kidney disease result in inflammation or does inflammation produce renal dysfunction? Are there inflammatory markers we could measure to assess this inflammation? Can we do anything to reduce the inflammation and if so, does it improve patient outcome? These are just some of the questions I'll be asking my guest, Aleksandra Kukla, M.D., from the Division of Nephrology at the Mayo Clinic as we discuss “Chronic Kidney Disease as a Systemic Inflammatory Syndrome”. These talks on Inflammation and Cardiometabolic Disease are sponsored by Novo Nordisk Learn more about this series HERE Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Dr. Centor discusses reninbngiotensin system blockade in persons with advanced chronic kidney disease with Drs. Elaine Ku and Mark Sarnak.

Did you miss AHA 2024? Listen here to brief discussions of the latest research. Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. DOI: 10.1056/NEJMe2414476.

Today on the podcast, we talk with Rebecca Grandy, Directory of Pharmacy at CHESS Health Solutions, about the connection between diabetes and chronic kidney disease, the populations who are at risk, how to address any concerns, and what tests and interventions are available to the provider. OK, so, Rebecca Grandy, welcome to the move to Value podcast. Could you start by explaining the connection between diabetes and chronic kidney disease and why it's so important to screen for these in diabetic and or for chronic kidney disease in diabetic patients?Sure. You know, diabetes is one of the leading causes of chronic kidney disease. I think there's lots of reasons for that. A lack of early screening, a lack of just knowing what to do, having accessible medicines. But all of those things now we have relatively good screenings, we have medications and so kidney disease and diabetes is present preventable. And then just from a, you know disease, state perspective, diabetes itself, the high glucoses, the inflammation on the high blood pressure, obesity, all of those things also increase your risk for chronic kidney disease and so you'll see a strong correlation between those two.And you know, it's also proven that minorities are disproportionately affected by chronic kidney disease and what steps do you think can be taken to address that as we start looking into our social determinants and our HealthEquity components of the quintuple aim?Wow, that's sort of a can of worms type of question, right? Because you know, when I think about minority populations or even just disparities in healthcare, I think there are lots of reasons for those. One is access and so primary care I think is the solution for that. And so being able to solve access issues to primary care, there are also issues like social determinants of health issues and so thinking through a lot of the work that ACOs are doing, like the REACH model, care coordination, social work, really being able to not only screen for social determinants of health, but to actually have solutions for those. And so I think that's happening slowly. You know, those screenings are starting to be incorporated into primary care, but if we can address some of those issues, I think we can solve access issues. The harder one in my mind to solve is sort of the historical like trauma and distrust that comes with minorities in the healthcare system. That one's harder, but I think. I think you know having minorities go into positions where they are providers, right? So I can see someone who culturally is like me, who looks like me, who I know has my best interest at heart. I think a lot of those pipelines for minorities to be healthcare providers, are really helpful as well.Yeah, I think that's definitely true. So some of our data at CHESS shows that you know up to 40% of people with diabetes do develop chronic kidney disease. Can you explain why early screening is so critical and how it impacts the progression of that disease?And I feel like I have to tell a story first. So, you know, when I was working in primary care, one of the most, I don't know, frustrating's the right word, but definitely discouraging things is when you see someone sitting in front of you that has a chronic condition that could have been prevented, right? And I feel like chronic kidney disease is one of those preventable conditions because when you have chronic kidney disease and you progressed in stage renal disease and you're on dialysis that kind of takes over your entire existence, right? Like those people are going to dialysis three times a week, you have to be really careful about the nutrition, about your protein intake. You have to be careful about all your medicines. You can't just go to your cabinet and reach for your ibuprofen. And so the fact that something that you know can be so significant or impact your lifestyle that...

First, she lost her younger brother to chronic kidney disease.Then last year, Ufuoma McDermott was also diagnosed of Stage 3 kidney disease - after battling with it for 12 years. She was told to slow down at work and rest. But she thought she had more time and negotiated with her doctors. That delay turned out to be costly. She was shortly diagnosed of Stage 4 kidney disease. Stage 4. That's the final stage. And she says it was a result of drug abuse - ingesting too many painkillers. Thus began a battle for her life, where there was zero room for error. For 6 months, she couldn't move. She couldn't work. She couldn't add weight. She actually thought the end had come. In this exclusive interview, the actor and producer shares how she found her way back from Stage 4 kidney disease, how it changed how she lived her life, how she managed her public career while dealing with this in private, and why this life-changing experience has transformed the way she lives her life today. Also for the first time, she confirms that over the past few years she has lived with her family abroad while acting and producing in Nigeria - and how a very private life has served her very well. This was one hell of a conversation.  Exclusive Patron-only Content Hosted on Acast. See acast.com/privacy for more information.

Imagine a treatment that not only helps manage diabetes but also holds the potential to reverse kidney failure — what was once thought to be impossible. The recent FLOW study has remarkable groundbreaking evidence that GLP-1 receptor agonists can significantly improve kidney function in chronic kidney disease (CKD) patients. And while researchers try to understand the full implications of these findings, one thing is clear: the landscape of kidney disease treatment may never be the same again.  In this podcast, we'll dive into the results of the FLOW trial and explore what they may mean for people at risk for kidney failure. What are GLP-1 Agonists? GLP-1 (glucagon-like peptide-1) agonists are a class of drugs that mimic the effects of the natural hormone GLP-1. They enhance insulin secretion, inhibit glucagon release, and slow gastric emptying, improving blood sugar control. Beyond their primary use in diabetes management, GLP-1 agonists have been studied for various conditions, including obesity and cardiovascular disease prevention. The Study Overview The FLOW trial, which stands for "Fasting and Long-acting GLP-1 Receptor Agonist in Patients with Chronic Kidney Disease," focused on the impact of GLP-1 receptor agonists, specifically semaglutide, on patients with chronic kidney disease (CKD) and type 2 diabetes (those most at risk for kidney failure). Researchers observed a remarkable trend: patients receiving semaglutide demonstrated stabilization of kidney function and signs of renal recovery. This was groundbreaking, as reversing kidney damage has long been considered a near-impossible feat. Study Objectives The primary goal was to determine whether treatment with GLP-1 receptor agonists could improve kidney outcomes in patients with CKD. Study Design Participants: The study enrolled >3500 adults with type 2 diabetes and CKD. Intervention: Participants were randomized to receive either semaglutide or a placebo. Primary Outcomes: The main outcomes included changes in glomerular filtration rate (GFR) and the incidence of major adverse kidney events (kidney failure- need for transplantation or dialysis). Key Findings Renal Function Improvement: Patients on semaglutide showed significant improvements in glomerular filtration rates (GFR), a key indicator of kidney function. Reduced Inflammation: The drugs appeared to lower levels of inflammatory markers associated with kidney damage, suggesting a protective effect. Metabolic Benefits: Improvements in blood sugar control and weight loss were also observed, contributing to overall health and potentially alleviating stress on the kidneys. Adverse Events: The treatment was generally well-tolerated, with a favorable safety profile. Ethical Considerations As the results began to emerge, the ethical landscape of the study shifted dramatically. The control group, which was not receiving semaglutide, was found to be at a significantly higher risk of kidney deterioration. With compelling evidence that the GLP-1 agonist was safe and potentially life-saving, the ethics committee determined withholding treatment from any participants was no longer justifiable. Consequently, the study was halted prematurely to allow all participants access to the medication, prioritizing patient welfare over the continuation of research under an inequitable framework. This decision underscores the ethical responsibility of researchers to ensure that all patients receive the best possible care, especially when clear benefits are identified. Implications for Future Research While the early termination of the study raises questions about the completeness of the data collected, it also opens new avenues for further research. The findings encourage more extensive clinical trials to explore the mechanisms behind the renal protective effects of GLP-1 agonists. Additionally, there is a growing interest in investigating these drugs' long-term effects on kidney health and their potential role in preventing disease progression. As further studies unfold, there is hope that GLP-1 agonists will become a standard part of kidney disease management, potentially transforming outcomes for millions affected by this condition. Thanks again for listening to The Peptide Podcast. We love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! We're huge advocates of elevating your health game with nutrition, supplements, and vitamins. Whether it's a daily boost or targeted support, we trust and use Momentous products to supercharge our wellness journey.  Momentous only uses the highest-quality ingredients, and every single product is rigorously tested by independent third parties to ensure their products deliver on their promise to bring you the best supplements on the market.

Same may think of the pathologist's toolbox as only the microscope and their eyes, but in reality today's pathologists are using more and more molecular methods like NGS and PCR in additional to their traditional tools. Meet Parker Wilson, MD, PhD. Parker is a faculty member Perelman School of Medicine at the University of Pennsylvania, focused on using modern molecular tools to investigate chronic kidney disease. He explains his work phenomenally, both from the general aspects, all the way down to the molecular methods, which include digital PCR. We learn about chronic kidney disease and the interesting genetic mutations associated with it, which Parker and his team are finding, include chromosomal loss. For this application, we hear how dPCR is adept at quantifying chromosome ratios within tissues, and is able to help them spot variations of only a single percent or two. Our career corner portion uncovers an academic and career path with uncertainty and challenges one might not expect. Parker helps normalize these challenges and underscores the value of mentors in helping navigate them successfully. In the end, you have a phenomenally intelligent physician scientists sharing his exciting work and his insightful career development advice.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

In this episode, Dr. Valentin Foster explores the October issue of JACC, which highlights obesity and the potential benefits of glucagon-like peptide receptor agonists, particularly semaglutide, in treating heart failure. He delves into the FLOW trial, revealing how semaglutide significantly reduced heart failure events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease, while also addressing the study's limitations and the need for improved diagnostic criteria in future research.

Send us a textUnlock the secrets to safeguarding your kidney health with insights from our special guest, Andrea, a dedicated dietetic intern passionate about chronic kidney disease (CKD). With CKD affecting one in seven Americans, this episode sheds light on its silent progression and the importance of early dietary interventions. Join us as we uncover the kidneys' vital role in waste elimination, electrolyte balance, and hydration, and emphasize the critical need for regular kidney function monitoring, especially as we age.As we journey through the challenges of maintaining kidney health in older adults, we explore the tricky balance of staying hydrated and controlling blood sugar levels in type 2 diabetes. Discover why plant-based proteins are emerging as a beneficial dietary choice for managing CKD and how collaborating with healthcare professionals can tailor your diet to your specific needs. Andrea shares compelling research findings, highlighting the astounding 70% decreased risk of CKD progression for those embracing a plant-forward lifestyle, underscoring the protective power of these dietary changes.We wrap up the episode by guiding you on how to connect with professional dietitians online at eatright.org. This resource is invaluable for anyone seeking personalized nutrition guidance from experts who understand the complexities of CKD and kidney health. We urge you to become an advocate for your own health, engage with your healthcare provider about kidney health, and prioritize expert dietary advice to stay healthy and safe. Thank you for tuning in to this enlightening discussion, and we look forward to sharing more vital health insights in our next episode!Nutrition Tips for CKD Thank you for listening. Please subscribe to this podcast and share with a friend. If you would like to know more about my services, please message at fueledbyleo@gmail.comMy YouTube Channel https://www.youtube.com/channel/UC0SqBP44jMNYSzlcJjOKJdg

Send us a textIn this special episode of The Incubator podcast, Ben and Daphna wrap up the 2024 Delphi Neonatal Innovation Conference, sharing their favorite moments and highlights. This episode features the exclusive audio from four captivating Delphi talks. Dr. Suresh Gautham, Chair of Pediatrics at Nemours Children's Hospital, opens with an intriguing talk on "What Neonatologists Can Learn from Sherlock Holmes," drawing parallels between neonatal practice and detective work. Dr. Terrie Inder from CHOC delivers insights in "The Science and Art of Improving Neurological Outcomes in NICU Graduates," blending research with practical care strategies. Pediatric nephrologist Chryso Pefkaros Katsoufis from the University of Miami explores "The Road Less Traveled? Neonatal Biomarkers of Chronic Kidney Disease," shedding light on innovative approaches to CKD in newborns. Finally, Dr. Lauren Ruoss, from Winnie Palmer Hospital, enchants the audience with "Abracadabra! Making POCUS Appear in the NICU," detailing the role of point-of-care ultrasound in neonatal care. Ben and Daphna conclude the episode by previewing exciting upcoming developments for The Incubator network. Don't miss this unique opportunity to hear from some of the leading voices in neonatal care. As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this special episode of The Incubator podcast, Ben and Daphna wrap up the 2024 Delphi Neonatal Innovation Conference, sharing their favorite moments and highlights. This episode features the exclusive audio from four captivating Delphi talks. Dr. Suresh Gautham, Chair of Pediatrics at Nemours Children's Hospital, opens with an intriguing talk on "What Neonatologists Can Learn from Sherlock Holmes," drawing parallels between neonatal practice and detective work. Dr. Terrie Inder from CHOC delivers insights in "The Science and Art of Improving Neurological Outcomes in NICU Graduates," blending research with practical care strategies. Pediatric nephrologist Chryso Pefkaros Katsoufis from the University of Miami explores "The Road Less Traveled? Neonatal Biomarkers of Chronic Kidney Disease," shedding light on innovative approaches to CKD in newborns. Finally, Dr. Lauren Ruoss, from Winnie Palmer Hospital, enchants the audience with "Abracadabra! Making POCUS Appear in the NICU," detailing the role of point-of-care ultrasound in neonatal care. Ben and Daphna conclude the episode by previewing exciting upcoming developments for The Incubator network. Don't miss this unique opportunity to hear from some of the leading voices in neonatal care.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this special episode of The Incubator podcast, Ben and Daphna wrap up the 2024 Delphi Neonatal Innovation Conference, sharing their favorite moments and highlights. This episode features the exclusive audio from four captivating Delphi talks. Dr. Suresh Gautham, Chair of Pediatrics at Nemours Children's Hospital, opens with an intriguing talk on "What Neonatologists Can Learn from Sherlock Holmes," drawing parallels between neonatal practice and detective work. Dr. Terrie Inder from CHOC delivers insights in "The Science and Art of Improving Neurological Outcomes in NICU Graduates," blending research with practical care strategies. Pediatric nephrologist Chryso Pefkaros Katsoufis from the University of Miami explores "The Road Less Traveled? Neonatal Biomarkers of Chronic Kidney Disease," shedding light on innovative approaches to CKD in newborns. Finally, Dr. Lauren Ruoss, from Winnie Palmer Hospital, enchants the audience with "Abracadabra! Making POCUS Appear in the NICU," detailing the role of point-of-care ultrasound in neonatal care. Ben and Daphna conclude the episode by previewing exciting upcoming developments for The Incubator network. Don't miss this unique opportunity to hear from some of the leading voices in neonatal care.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this special episode of The Incubator podcast, Ben and Daphna wrap up the 2024 Delphi Neonatal Innovation Conference, sharing their favorite moments and highlights. This episode features the exclusive audio from four captivating Delphi talks. Dr. Suresh Gautham, Chair of Pediatrics at Nemours Children's Hospital, opens with an intriguing talk on "What Neonatologists Can Learn from Sherlock Holmes," drawing parallels between neonatal practice and detective work. Dr. Terrie Inder from CHOC delivers insights in "The Science and Art of Improving Neurological Outcomes in NICU Graduates," blending research with practical care strategies. Pediatric nephrologist Chryso Pefkaros Katsoufis from the University of Miami explores "The Road Less Traveled? Neonatal Biomarkers of Chronic Kidney Disease," shedding light on innovative approaches to CKD in newborns. Finally, Dr. Lauren Ruoss, from Winnie Palmer Hospital, enchants the audience with "Abracadabra! Making POCUS Appear in the NICU," detailing the role of point-of-care ultrasound in neonatal care. Ben and Daphna conclude the episode by previewing exciting upcoming developments for The Incubator network. Don't miss this unique opportunity to hear from some of the leading voices in neonatal care.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textIn this special episode of The Incubator podcast, Ben and Daphna wrap up the 2024 Delphi Neonatal Innovation Conference, sharing their favorite moments and highlights. This episode features the exclusive audio from four captivating Delphi talks. Dr. Suresh Gautham, Chair of Pediatrics at Nemours Children's Hospital, opens with an intriguing talk on "What Neonatologists Can Learn from Sherlock Holmes," drawing parallels between neonatal practice and detective work. Dr. Terrie Inder from CHOC delivers insights in "The Science and Art of Improving Neurological Outcomes in NICU Graduates," blending research with practical care strategies. Pediatric nephrologist Chryso Pefkaros Katsoufis from the University of Miami explores "The Road Less Traveled? Neonatal Biomarkers of Chronic Kidney Disease," shedding light on innovative approaches to CKD in newborns. Finally, Dr. Lauren Ruoss, from Winnie Palmer Hospital, enchants the audience with "Abracadabra! Making POCUS Appear in the NICU," detailing the role of point-of-care ultrasound in neonatal care. Ben and Daphna conclude the episode by previewing exciting upcoming developments for The Incubator network. Don't miss this unique opportunity to hear from some of the leading voices in neonatal care.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Catherine Yeung, Pharm.D., Ph.D., M.P.H., discusses groundbreaking advancements in kidney-on-a-chip technology, emphasizing its potential to revolutionize human health. She delves into the role of environmental toxins, such as okra toxin A, microplastics, and plasticizers, in contributing to chronic kidney disease, particularly in regions with specific dietary practices. Yeung also addresses the challenges of replicating adult kidney cells from stem cells, which often retain a fetal phenotype, and underscores the value of stem cell-derived models for genetic manipulation and disease research. Additionally, she highlights the increased risk of kidney stones in astronauts post-spaceflight and the broader implications of organ-on-chip technology for studying therapies and diseases. Series: "Women in Science" [Health and Medicine] [Science] [Show ID: 39458]

Catherine Yeung, Pharm.D., Ph.D., M.P.H., discusses groundbreaking advancements in kidney-on-a-chip technology, emphasizing its potential to revolutionize human health. She delves into the role of environmental toxins, such as okra toxin A, microplastics, and plasticizers, in contributing to chronic kidney disease, particularly in regions with specific dietary practices. Yeung also addresses the challenges of replicating adult kidney cells from stem cells, which often retain a fetal phenotype, and underscores the value of stem cell-derived models for genetic manipulation and disease research. Additionally, she highlights the increased risk of kidney stones in astronauts post-spaceflight and the broader implications of organ-on-chip technology for studying therapies and diseases. Series: "Women in Science" [Health and Medicine] [Science] [Show ID: 39458]

In this episode, Dr. Valentin Fuster discusses a comprehensive review on the challenges and considerations of using implantable cardiography devices in patients with advanced chronic kidney disease and heart failure. Highlighting key findings from Dr. Cecilia Barca's research, he explores the nuanced interplay between these conditions and device efficacy, emphasizing the need for tailored patient evaluations and future studies to improve outcomes.

In this episode, Dr. Valentin Fuster discusses groundbreaking research on the interplay between cardiovascular risk factors and chronic kidney disease (CKD) progression among Chinese adults. Highlighting a study that reveals how effective management of hypertension, cholesterol, and blood glucose can significantly reduce the risks of cardiovascular events and mortality in CKD patients, the conversation emphasizes the crucial need for targeted treatment strategies to improve patient outcomes.

Send us a textNicole grew up wanting for nothing. As a result, she did not develop coping skills for life and turned to pills to face lifes challenges. Despite her success in life, she found herself hopelessly addicted to IV opioids and trapped in an extremely violent relationship. Today she is 8 years in recovery and has dedicated her life to carrying a message and helping people who are lost like she was.Check out Nicole on Tiktok https://www.tiktok.com/@the.victorious.sober.one?_t=8pYbnbo6y4E&_r=1✅ Check out EHN Canada https://www.edgewoodhealthnetwork.com/✅ Pine Lodge Recovery https://pinelodgerecovery.ca/✅Métis Nation Saskatchewan https://metisnationsk.com/ourmoment/✅Bunny Hugs and Mental Health https://linktr.ee/bunnyhugspodcast✅Wellness News https://qrco.de/bbapw8Support the showWe've got fresh merch and it's amazing! Pick yours up HERE Are you getting something from our content? Tap here and buy us a coffee to say thanks and help us keep this train on the tracks! Check us out on YouTube:https://www.youtube.com/@hardknoxtalks

Chronic Kidney Disease (CKD) is a serious complication of diabetes that often goes unnoticed in its early stages. In this episode of the Taking Control of Your Diabetes podcast, hosts Dr. Jeremy Pettus and Dr. Steve Edelman, both endocrinologists living with type 1 diabetes, provide an in-depth exploration of CKD in diabetes. They discuss the prevalence, screening methods, and latest treatment options for diabetic kidney disease, focusing on type 1 diabetes. Dr. Edelman also shares his personal experience managing CKD.In this episode, we will talk about:The prevalence and impact of kidney disease in type 1 diabetesHow diabetes affects kidney functionScreening tests for diabetic kidney disease: eGFR and UACRUnderstanding the stages of chronic kidney diseaseThe ABCs of diabetes management for kidney health: A1C, Blood pressure, and CholesterolLifestyle factors in preventing and managing kidney diseaseMedications to use and avoid with kidney diseaseThe role of ACE inhibitors and SGLT2 inhibitors in kidney protectionChallenges and considerations for people with type 1 diabetes regarding new kidney treatmentsDr. Steve Edelman's personal journey with CKDThe importance of proactive management and regular monitoring ★ Support this podcast ★

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Moving beyond lipid lowering to address residual inflammatory riskNovel anti-inflammatory targets for ASCVD To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clipsClinicalThought commentariesPodcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.    Episode outline:   The relationship among systemic inflammation, ASCVD, and CKD The role of cardiologists and nephrologists in screening and mitigating systemic inflammation To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 

Welcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. John Fralick and Justin Boyle discuss two recent papers exploring the role of semaglutide in CKD in patients with Type II Diabetes and the utility of tirzepatide in metabolic dysfunction-associated steatohepatitis with liver fibrosis. Two papers, here we go!Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (0:00 – 09:32).Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (09:32 – 17:06).And for the Good Stuff:Congratulations to everyone starting/progressing through residency/finishing their training! (17:06 – 17:43).Calgary officials aiming for 'low end' of repair timeline after pipes arrive from San Diego (17:43 – 19:06).Questions? Comments? Feedback? We'd love to hear from you! @roundstable

Today, Fei and Nick discuss chronic kidney disease and pregnancy. What do we need to know about CKD, and how does it affect pregnancy outcomes?  A new exciting announcement: we have started OB/Gyn GOALS, located at obgyngoals.org. This is a free, weekly residency curriculum focused on CREOG learning objectives. Sign up now to receive your weekly lesson!  Twitter: @creogsovercoff1 Instagram: @creogsovercoffee Facebook: www.facebook.com/creogsovercoffee Website: www.creogsovercoffee.com Patreon: www.patreon.com/creogsovercoffee You can find the OBG Project at: www.obgproject.com

Pharmacists looking to enhance their knowledge about Chronic Kidney Disease (CKD) can take advantage of a special two-part series from i3Health, in partnership with ConveyMed. This educational series delves into various aspects of CKD, providing comprehensive insights crucial for pharmacy professionals. Not only does this series offer valuable information, but it also includes 1.5 total continuing education credits, making it an excellent opportunity for pharmacists to advance their expertise while fulfilling their continuing education requirements.   Special Guest Jeff Sperry, PharmD, BCPS Clinical Pharmacist, Internal Medicine UCHealth Memorial Hospital Next, we talk with Danielle Greer, VP of Product Development and Dr. Mark Fulton, PharmD, the host of Framework Focus about the SoftWriters dedication to AI in LTC Pharmacy.